CN113101292B - 双炔失碳酯组合物和疾病治疗方法 - Google Patents

双炔失碳酯组合物和疾病治疗方法 Download PDF

Info

Publication number
CN113101292B
CN113101292B CN202110246492.2A CN202110246492A CN113101292B CN 113101292 B CN113101292 B CN 113101292B CN 202110246492 A CN202110246492 A CN 202110246492A CN 113101292 B CN113101292 B CN 113101292B
Authority
CN
China
Prior art keywords
certain embodiments
alkyl
alkenyl
mandipropamid
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110246492.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN113101292A (zh
Inventor
杨军
施惠娟
徐文平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute Of Biomedical Technology
Original Assignee
Shanghai Institute Of Biomedical Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute Of Biomedical Technology filed Critical Shanghai Institute Of Biomedical Technology
Priority to CN202110246492.2A priority Critical patent/CN113101292B/zh
Publication of CN113101292A publication Critical patent/CN113101292A/zh
Application granted granted Critical
Publication of CN113101292B publication Critical patent/CN113101292B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN202110246492.2A 2014-05-08 2014-05-08 双炔失碳酯组合物和疾病治疗方法 Active CN113101292B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110246492.2A CN113101292B (zh) 2014-05-08 2014-05-08 双炔失碳酯组合物和疾病治疗方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202110246492.2A CN113101292B (zh) 2014-05-08 2014-05-08 双炔失碳酯组合物和疾病治疗方法
CN201410192569.2A CN104208069A (zh) 2014-05-08 2014-05-08 双炔失碳酯组合物和疾病治疗方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201410192569.2A Division CN104208069A (zh) 2014-05-08 2014-05-08 双炔失碳酯组合物和疾病治疗方法

Publications (2)

Publication Number Publication Date
CN113101292A CN113101292A (zh) 2021-07-13
CN113101292B true CN113101292B (zh) 2023-07-11

Family

ID=52090245

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202110246492.2A Active CN113101292B (zh) 2014-05-08 2014-05-08 双炔失碳酯组合物和疾病治疗方法
CN202010899146.XA Active CN111956653B (zh) 2014-05-08 2014-05-08 双炔失碳酯组合物和疾病治疗方法
CN201410192569.2A Pending CN104208069A (zh) 2014-05-08 2014-05-08 双炔失碳酯组合物和疾病治疗方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202010899146.XA Active CN111956653B (zh) 2014-05-08 2014-05-08 双炔失碳酯组合物和疾病治疗方法
CN201410192569.2A Pending CN104208069A (zh) 2014-05-08 2014-05-08 双炔失碳酯组合物和疾病治疗方法

Country Status (5)

Country Link
US (3) US10231978B2 (enExample)
EP (1) EP3139928B1 (enExample)
JP (4) JP6594339B2 (enExample)
CN (3) CN113101292B (enExample)
WO (1) WO2015169173A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113101292B (zh) 2014-05-08 2023-07-11 上海市生物医药技术研究院 双炔失碳酯组合物和疾病治疗方法
CN105279394B (zh) * 2015-10-13 2017-12-26 山西农业大学 用于神经肽受体筛选的方法
JP6788255B2 (ja) * 2015-11-19 2020-11-25 国立大学法人信州大学 新規ベクター及びこれを用いた可溶化タンパク質の製造方法
IL284875B (en) 2016-10-11 2022-07-01 Univ Duke Zofoxifene treatment for breast cancer
US11040054B2 (en) 2016-11-14 2021-06-22 The Brigham And Women's Hospital, Inc. Estrogen sensing through GPER1 regulates normal and malignant liver growth
EP3568132B1 (en) 2017-01-10 2025-12-03 Wang, Wei Lasofoxifene modulation of membrane-initiated estrogen signals and methods for tumor treatment
WO2019041078A1 (en) * 2017-08-28 2019-03-07 Zhejiang Jiachi Pharmaceutical Development Ltd. ASYMMETRIC SYNTHESIS AND USES OF COMPOUNDS IN TREATMENT OF DISEASES
CN109662968B (zh) * 2017-10-13 2021-05-18 上海奥奇医药科技有限公司 含A-失碳-5α雄甾烷化合物的升白制剂及其应用
EP3773524B1 (en) 2018-04-10 2025-04-09 Duke University Lasofoxifene for the treatment of er+ breast cancer carrying the mutation d538g or y537s
CN111773388B (zh) * 2019-04-04 2023-07-18 上海奥奇医药科技有限公司 A-失碳-5α雄甾烷化合物类药物与抗癌药物的联合应用
US20210299098A1 (en) * 2020-03-31 2021-09-30 Cipla Limited Selective estrogen receptor modulator for treatment of pancreatic cancer
WO2022246634A1 (en) * 2021-05-25 2022-12-01 Zhejiang Jiachi Development Pharmaceuticals Ltd. Compositions for treating insomnia and uses thereof
GB202116903D0 (en) 2021-11-18 2022-01-05 Sermonix Pharmaceuticals Inc Lasofoxifene treatment of aromatase-resistant er+ cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001120A (en) * 1989-05-10 1991-03-19 Natural Pharmacia International, Inc. Use of A-Nor-steroids as malignant cells growth inhibitors
CN101987081A (zh) * 2010-07-16 2011-03-23 钟术光 一种控释制剂

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7985422B2 (en) * 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
MXPA05003054A (es) * 2002-09-20 2005-05-27 Pfizer Prod Inc Ligandos de amida y sulfonamida para el receptor de estrogenos.
WO2005048942A2 (en) * 2003-11-13 2005-06-02 Pharmacia Corporation Combination therapy comprising a cox-2 inhibitor and an antineoplastic agent
JP2008505079A (ja) * 2004-06-30 2008-02-21 メルク　エンド　カムパニー　インコーポレーテッド エストロゲン受容体調節剤
US20090215731A1 (en) 2005-10-19 2009-08-27 Chavah Pty Ltd. Reduction of Side Effects From Aromatase Inhibitors Used for Treating Breast Cancer
CN101297970A (zh) * 2006-03-17 2008-11-05 山东蓝金生物工程有限公司 同载抗代谢药物及其增效剂的抗癌缓释注射剂
WO2007129062A1 (en) 2006-05-08 2007-11-15 Astex Therapeutics Limited Pharmaceutical combinations of diazole derivatives for cancer treatment
US9220771B2 (en) 2010-07-16 2015-12-29 Merck Patent Gmbh Peptide for use in the treatment of breast cancer and/or bone metastases
CN103562226A (zh) 2011-03-11 2014-02-05 梅里麦克制药股份有限公司 使用egfr家族受体的抑制剂来治疗激素难治性乳腺癌
CN102218069B (zh) * 2011-04-08 2012-09-26 上海奥奇医药科技有限公司 A-失碳-5α-雄甾烷化合物在制备抗恶性肿瘤药物中的应用
CN113101292B (zh) 2014-05-08 2023-07-11 上海市生物医药技术研究院 双炔失碳酯组合物和疾病治疗方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5001120A (en) * 1989-05-10 1991-03-19 Natural Pharmacia International, Inc. Use of A-Nor-steroids as malignant cells growth inhibitors
CN101987081A (zh) * 2010-07-16 2011-03-23 钟术光 一种控释制剂

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy;Virginia Haurigot et al.,;《The Journal of Clinical Investigation》;第123卷(第8期);第3254-3271页 *
α－双炔失碳酯及其代谢产物双炔失碳醇的体外抗肿瘤作用比较;顾健，胥彬;肿瘤(第02期);全文 *
α-双炔失碳酯对人卵巢癌细胞生长的影响及其与ER的关系;冯炜炜,曹斌融,丰有吉;现代妇产科进展(第04期);全文 *
米非司酮和米索前列醇配伍双炔失碳酯减少药物流产失血量的研究;黄晓燕,林小娜,陈湫波;宁波医学(第04期);全文 *

Also Published As

Publication number Publication date
CN113101292A (zh) 2021-07-13
WO2015169173A1 (en) 2015-11-12
EP3139928B1 (en) 2025-03-05
EP3139928C0 (en) 2025-03-05
US10857158B2 (en) 2020-12-08
CN104208069A (zh) 2014-12-17
US10231978B2 (en) 2019-03-19
JP2017514853A (ja) 2017-06-08
JP2022078330A (ja) 2022-05-24
CN111956653A (zh) 2020-11-20
JP7084467B2 (ja) 2022-06-14
JP2021050241A (ja) 2021-04-01
US20170151263A1 (en) 2017-06-01
US11911397B2 (en) 2024-02-27
JP6594339B2 (ja) 2019-10-23
EP3139928A4 (en) 2017-12-13
JP2019142969A (ja) 2019-08-29
US20190262360A1 (en) 2019-08-29
US20210069212A1 (en) 2021-03-11
EP3139928A1 (en) 2017-03-15
CN111956653B (zh) 2023-06-30

Similar Documents

Publication Publication Date Title
CN113101292B (zh) 双炔失碳酯组合物和疾病治疗方法
Han et al. Triptolide inhibits the AR signaling pathway to suppress the proliferation of enzalutamide resistant prostate cancer cells
CN115737636B (zh) 拉索昔芬调节膜结合雌激素信号的应用及治疗癌症的方法
Zheng et al. Metapristone suppresses non-small cell lung cancer proliferation and metastasis via modulating RAS/RAF/MEK/MAPK signaling pathway
Lee et al. Tissue transglutaminase activates cancer-associated fibroblasts and contributes to gemcitabine resistance in pancreatic cancer
Shiah et al. Inhibition of cell growth and nuclear factor-κB activity in pancreatic cancer cell lines by a tylophorine analogue, DCB-3503
Shao et al. Liver X receptor agonism sensitizes a subset of hepatocellular carcinoma to sorafenib by dual-inhibiting MET and EGFR
Garg et al. A novel approach of targeting refractory epilepsy: Need of an hour
Zhan et al. A novel taspine derivative, HMQ1611, inhibits breast cancer cell growth via estrogen receptor α and EGF receptor signaling pathways
US20160339004A1 (en) Pharmaceutical compositions and methods for treating cancer and biomarkers for drug screening
EP2370175A2 (en) Methods of inhibiting quiescent tumor proliferation
Gorska‑Ponikowska et al. of mitochondrial dynamics in 2‑methoxyestradiol‑mediated osteosarcoma cell death
Giró Perafita Fatty acid synthase expression and inhibition in triple-negative breast cancer
Dai et al. Nur77 knock-down suppresses glioma by regulating CXCR4
JP2017536353A (ja) がん治療のための医薬組成物及び薬物スクリーニング用バイオマーカー
ETOPOSIDE and validation
HK1241730A1 (en) Composition for treating cancer stem cells

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: 200032 Shanghai Xuhui District Xietu Road No. 2140

Applicant after: Shanghai Institute of biomedical technology

Address before: Room 502, building 2, no.2140 Xietu Road, Xuhui District, Shanghai 200032

Applicant before: SHANGHAI INSTITUTE OF PLANNED PARENTHOOD RESEARCH

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant